Hilton Head Capital Partners LLC Makes New $1.41 Million Investment in Medtronic PLC $MDT

Hilton Head Capital Partners LLC bought a new position in shares of Medtronic PLC (NYSE:MDT) in the fourth quarter, HoldingsChannel reports. The firm bought 14,667 shares of the medical technology company’s stock, valued at approximately $1,409,000. Medtronic comprises about 0.8% of Hilton Head Capital Partners LLC’s holdings, making the stock its 26th biggest holding.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Lodestone Wealth Management LLC acquired a new position in Medtronic during the fourth quarter worth about $27,000. Anfield Capital Management LLC raised its position in Medtronic by 410.7% during the fourth quarter. Anfield Capital Management LLC now owns 286 shares of the medical technology company’s stock worth $27,000 after acquiring an additional 230 shares during the last quarter. Board of the Pension Protection Fund acquired a new position in Medtronic during the fourth quarter worth about $29,000. GoalVest Advisory LLC acquired a new position in Medtronic during the fourth quarter worth about $29,000. Finally, Imprint Wealth LLC acquired a new position in Medtronic during the third quarter worth about $31,000. Institutional investors and hedge funds own 82.06% of the company’s stock.

Trending Headlines about Medtronic

Here are the key news stories impacting Medtronic this week:

• Positive Sentiment: Medtronic’s fiscal Q4 results beat revenue expectations and showed continued year-over-year growth, while management signaled confidence in the company’s FY26/FY27 growth outlook and new product platforms. Medtronic (MDT) Climbs 5.7% on Stellar Q4
• Positive Sentiment: BTIG upgraded Medtronic to Buy with a $90 target, citing a strong revenue beat and improving organic growth, while other firms such as TD Cowen and RBC reaffirmed bullish ratings. Wall Street May Be Mispricing Medtronic, Analyst Says
• Positive Sentiment: Medtronic expanded its relationship with Retia Medical to distribute the Argos Cardiac Output Monitor across Western Europe, adding to its cardiovascular portfolio and international reach. Retia Medical Expands Distribution of Argos® Cardiac Output Monitor to Western Europe with Medtronic
• Positive Sentiment: Medtronic also announced a higher quarterly dividend, signaling confidence in cash generation and shareholder returns. Medtronic (MDT) Climbs 5.7% on Stellar Q4
• Neutral Sentiment: Several brokerages lowered price targets after earnings, but most still kept Buy/Outperform or Hold/Neutral ratings, suggesting a reset in expectations rather than a major change in long-term views. Rothschild & Co Redburn cuts Medtronic price target
• Neutral Sentiment: Analyst roundups highlighted that Wall Street’s average recommendation remains Buy, but those consensus ratings are often viewed as overly optimistic and not always predictive. Is Medtronic (MDT) a Buy as Wall Street Analysts Look Optimistic?
• Negative Sentiment: Medtronic is still dealing with ongoing cardiovascular device recalls tied to potential sterile barrier issues, which could weigh on investor sentiment and create some execution risk. Medtronic Balances Hugo Robotics Expansion With Ongoing Cardiovascular Device Recalls

Analysts Set New Price Targets

MDT has been the subject of a number of research reports. Evercore set a $106.00 target price on shares of Medtronic and gave the stock an “outperform” rating in a research report on Thursday, April 9th. Argus cut their price objective on shares of Medtronic from $125.00 to $115.00 and set a “buy” rating for the company in a research report on Monday, April 6th. Royal Bank Of Canada reissued an “outperform” rating and issued a $118.00 price objective on shares of Medtronic in a research report on Thursday. The Goldman Sachs Group cut their price objective on shares of Medtronic from $84.00 to $83.00 and set a “neutral” rating for the company in a research report on Thursday. Finally, UBS Group cut their price objective on shares of Medtronic from $90.00 to $85.00 and set a “neutral” rating for the company in a research report on Thursday. Seventeen equities research analysts have rated the stock with a Buy rating and eleven have assigned a Hold rating to the company’s stock. According to data from MarketBeat, Medtronic has a consensus rating of “Moderate Buy” and a consensus target price of $99.00.

Medtronic Stock Performance

NYSE:MDT opened at $81.66 on Monday. The firm has a 50 day simple moving average of $81.46 and a 200-day simple moving average of $92.01. The company has a debt-to-equity ratio of 0.57, a current ratio of 2.54 and a quick ratio of 1.87. The firm has a market cap of $104.84 billion, a PE ratio of 21.89, a P/E/G ratio of 1.99 and a beta of 0.58. Medtronic PLC has a 1-year low of $73.31 and a 1-year high of $106.33.

Medtronic (NYSE:MDT) last posted its quarterly earnings data on Wednesday, June 3rd. The medical technology company reported $1.55 earnings per share for the quarter, beating analysts’ consensus estimates of $1.54 by $0.01. Medtronic had a net margin of 13.20% and a return on equity of 14.61%. The business had revenue of $9.81 billion during the quarter, compared to analyst estimates of $9.62 billion. During the same quarter in the previous year, the business posted $1.62 earnings per share. The company’s revenue was up 9.9% on a year-over-year basis. Medtronic has set its FY 2027 guidance at 5.900-6.000 EPS. On average, equities analysts expect that Medtronic PLC will post 5.94 EPS for the current year.

Medtronic Increases Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, July 17th. Investors of record on Friday, June 26th will be issued a $0.72 dividend. The ex-dividend date is Friday, June 26th. This is a positive change from Medtronic’s previous quarterly dividend of $0.71. This represents a $2.88 dividend on an annualized basis and a yield of 3.5%. Medtronic’s payout ratio is presently 76.14%.

Medtronic Company Profile

Medtronic plc is a global medical technology company that develops and manufactures a broad range of therapeutic devices and health care solutions. Headquartered legally in Ireland with principal operational offices in the United States, the company markets products to hospitals, physicians and health systems worldwide and has grown from its founding in 1949 into one of the largest medical-device manufacturers serving global health-care markets.

Medtronic’s offerings span several clinical areas, including cardiac rhythm and heart failure (pacemakers, implantable cardioverter?defibrillators and related cardiac therapies), minimally invasive and surgical technologies (laparoscopic and advanced energy devices, visualization systems and surgical innovations), restorative therapies (spine and orthopedics, neuromodulation and neurovascular treatments) and diabetes management (insulin-delivery systems and glucose monitoring solutions).